Chagas disease affects approximately 7 million people around the world as part of the group of Neglected Tropical Diseases (NTDs). The disease is endemic in Latin America, with the etiologic agent the protozoan Trypanosoma cruzi and its transmission occurs mainly through an insect vector, the triatomine. There are numerous studies involving this trypanosomiasis and increased adversity found by researchers is finding therapeutic alternatives for the treatment of disease, because the existing drugs have limited efficacy in chronic phase and bring numerous toxic effects, mainly related to oxidative stress, which is generated due to the active compound of the drug, and is a natural part of an infectious process. Studies using antioxidants in disease therapy have been conducted and the results are promising. In this project will be used melatonin, ascorbic acid and cyanocobalamin, substances whose antioxidant action has been widely studied, isolated and associated with benznidazole in order to verify their therapeutic potential. They will be perfomed in vitro biological assays on amastigotes of Trypanosoma cruzi using LLCMK2 cell line and in vivo protocols, performed in the acute phase of infection using an experimental model mice. The evaluated parameters are advancing infection in vivo tests, the development of amastigotes in vitro tests as well as the cytotoxicity of the substances evaluated. The parasitemia in animals will be determined and parasitism will be assessed by qPCR. In addition, assays which indicate the concentration of reactive oxygen species may be additionally performed to confirm the therapeutic effect.
News published in Agência FAPESP Newsletter about the scholarship: